Olmesartan Medoxomilo + Hidroclorotiazida Aurovitas (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide is used to manage blood pressure through the renin‑angiotensin system and diuretic pathways.

• Hypertension: helps lower systolic and diastolic blood pressure in adults.
• Hypertensive urgency: provides additional control when rapid reduction is needed under supervision.
• Resistant hypertension: assists when blood pressure remains uncontrolled despite other therapies.

• Olmesartan medoxil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis. Together they reduce vascular resistance and plasma volume, leading to a sustained decrease in blood pressure.

Side effects may vary in frequency and severity.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Increased urination
• Electrolyte imbalance (low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood cell disorders (e.g., neutropenia).

Patients should be evaluated for cardiovascular and renal status before starting therapy.

• Monitor blood pressure: ensure target levels are achieved without excessive drop.
• Assess renal function: adjust dose if creatinine clearance is reduced.
• Check electrolytes: watch for sodium and potassium disturbances.
• Avoid in pregnancy: drug may harm the fetus.
• Caution with elderly: start at lower dose and monitor closely.
• Store below 25°C: keep in the original packaging, protect from moisture.

Olmesartan medoxil and hydrochlorothazole may interact with several medicines.

Major Interactions (Avoid)

• Potassium‑rich supplements: risk of hyperkalemia.
• Aliskiren: combined renin‑angiotensin blockade can increase renal impairment.
• NSAIDs: may blunt antihypertensive effect and affect kidney function.

Moderate Interactions (Monitor Closely)

• Lithium: increased lithium levels and toxicity risk.
• Diuretics other than hydrochlorothiazide: additive electrolyte changes.
• ACE inhibitors: may increase risk of angio‑edema.
• Antidiabetic drugs: may enhance hypoglycaemic effect.
• Antifungal azoles (e.g., ketoconazole): may raise olmesartan levels.